Burkitt’s lymphoma (BL) is a rare form of non-Hodgkin’s lymphoma in which the cancer starts in the immune B-cells. We report the synthesis and preliminary studies on the antiproliferative activity of a library of 9,10-dihydro-9,10-ethanoanthracene based compounds structurally related to the antidepressant drug maprotiline against BL cell lines MUTU-1 and DG-75. Structural modifications were achieved by Diels-Alder
淋巴瘤(淋巴系统癌)占全世界恶性疾病的12%。伯基特氏淋巴瘤(BL)是非霍奇
金淋巴瘤的一种罕见形式,其癌症始于免疫B细胞。我们报告了9,10-dihydro-9,10-ethanananthracene基化合物与抗抑郁药Maprotiline对BL
细胞系MUTU-1和DG-75结构相关的化合物的合成和抗增殖活性的初步研究。通过使9-(2-
硝基乙烯基)
蒽核心与许多亲二
烯体包括
马来酸酐,马来
酰亚胺,
丙烯腈和
苯炔的狄尔斯-阿尔德反应进行结构修饰。在BL
细胞系EBV- MUTU-1和EBV + DG-75(耐
化学性)中评估了这些化合物的抗增殖活性。最有效的化合物13j,15、16a,16b,16c,图16d和19a显示的相对于BL
细胞系EBV- MUTU-1的IC50值在0.17–0.38μM范围内,相对于耐
化学性BL
细胞系EBV + DG-75的IC50值在0.45–0.78μM范围内。化合物1